ANGPT2
ENSG00000091879
Target class
Unclassified protein
Chromosome
8
Approved drugs
1
Clinical candidates (approved and in development)
8
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 8
- Chemical probe available
- No
- Other names
- Ang2
- Target name
- ANGPT2
- Gene name
- Angiopoietin 2
- Gene symbol
- ANGPT2
- Protein name
- Angiopoietin-2 (ANG-2)
- Gene biotype
- Protein coding
- Gene family
- Receptor ligands|Fibrinogen C domain containing|Angiopoietins
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 40
- Highest tissue expression
- 17.7
- Tissue specificity (Gini)
- 0.517
- Tissue specificity (tau)
- 0.848
- KEGG gene identifiers
- hsa:285
- Reactome pathways
- R-HSA-210993
- Protein interaction confidence
- 0.815634
- Protein interaction partners
- 41
- End position
- 6563409
- Start position
- 6499632
- Chromosome
- 8
- Strand
- Reverse
- Secreted .
Publication evidence
- PubMed 32908006
- Tissue specificity (tau)
- 0.848342
- Expression inequality (Gini)
- 0.516811
Expression in transcripts per million
- Artery - Tibial
- 17.7
- Adipose - Subcutaneous
- 13.27
- Adipose - Visceral (Omentum)
- 10.87
- Thyroid
- 9.54
- Breast - Mammary Tissue
- 8.27
Expression in transcripts per million
- Artery - Tibial17.7
- Adipose - Subcutaneous13.27
- Adipose - Visceral (Omentum)10.87
- Thyroid9.54
- Breast - Mammary Tissue8.27
- Artery - Coronary6.13
- Artery - Aorta5.44
- Fallopian Tube5.05
- Kidney - Medulla4.56
- Cervix - Endocervix4.18
- Cervix - Ectocervix4.04
- Nerve - Tibial3.93
- Bladder3.91
- Lung3.77
- Uterus3.75
- Brain - Spinal cord (cervical c-1)3.49
- Vagina3.12
- Prostate3.08
- Skin - Sun Exposed (Lower leg)2.49
- Esophagus - Muscularis2.49
- Ovary2.32
- Esophagus - Gastroesophageal Junction2.19
- Brain - Hypothalamus2.18
- Brain - Substantia nigra2.17
- Heart - Atrial Appendage2.09
And 29 more, listed on the interactive page.
- GO:0001525
- GO:0007165
- GO:0010467
- GO:0043537
- GO:0048014
- GO:0050820
- GO:0050928
Cellular components
- GO:0005576
- GO:0005102
- GO:0005515
- GO:0030971
- GO:0048018
Related records
Trials (98)
- A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function
- A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors
- A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid Tumors
- A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
- A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma
- A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
- A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome
- A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)
- A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
- A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer
- A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe
- A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema
- A Study of LY3127804 in Participants With COVID-19
- A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
- A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration
- A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer
- A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
- A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
- A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema
- A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)
Drugs (8)
- AMG-780 Angiopoietin-2 inhibitor
- CVX-060 Angiopoietin-2 inhibitor
- Faricimab Angiopoietin-2 inhibitor
- MEDI-3617 Angiopoietin-2 inhibitor
- Nesvacumab Angiopoietin-2 inhibitor
- Trebananib Angiopoietin-2 inhibitor
- Vanucizumab Angiopoietin-2 inhibitor
- Zansecimab Angiopoietin-2 inhibitor